Instituto Grifols, S.A.

Clinical trials sponsored by Instituto Grifols, S.A., explained in plain language.

Now part of Grifols, S.A. GRFS NASDAQ

Spanish subsidiary of a global plasma-derived medicines company, focusing on research and development.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1 Terminated 2

New eye drop aims to soothe dry, irritated eyes

Symptom relief Completed

This study tests an experimental eye drop called GRF312 5% in 100 adults with dry eye disease. The goal is to see if it is safe and helps relieve symptoms. Participants will use the drops at home and attend clinic visits for check-ups.

Phase 2 • Sponsor: Instituto Grifols, S.A. • Aim: Symptom relief

Last updated Jun 27, 2026 14:00 UTC

Instituto Grifols, S.A.

New eye drop aims to soothe dry, irritated eyes